Results 71 to 80 of about 17,638 (200)
International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Case Reports in Oncology, 2014 Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease.
Donato Callegaro-Filho +4 more
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju +6 more
wiley +1 more source
, 2019 Kaplan-Meier survival curves of mouse groups are shown. (A) comparison of all groups. (B) Daily IP topotecan versus daily IP saline control. (C) Daily IP topotecan, daily IVT topotecan, or continuous IVT topotecan infusion via pump.
Ellis F. Meng (6175520) +8 more
core +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot +6 more
wiley +1 more source
Mechanism-based models for topotecan-induced neutropenia
, 2004 OBJECTIVE: A semiphysiologic pharmacokinetic-pharmacodynamic model was applied to describe topotecan-induced neutropenia, to quantify interindividual and intraindividual pharmacodynamic variability, and to study the effect of covariates on the model ...
Bugat, R +14 more
core +1 more source
Advanced Science, Volume 13, Issue 49, 3 September 2026.A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu +17 more
wiley +1 more source
Plasma and tumor topotecan pharmacokinetics (PK).
, 2012 A, Plasma topotecan PK. Abcg2−/− animals, carrying ABCG2-positive tumor T1 (Fig. 2C), were treated with either vehicle +0.5 mg topotecan (green line) or 10 mg Ko143+0.5 mg topotecan (red line) per kg body weight and plasma was collected at 15, 30, 60, 90
Sven Rottenberg (135593) +7 more
core +1 more source
A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Background Atypical teratoid/rhabdoid tumors (ATRTs) are aggressive pediatric brain tumors that are sensitive to proteasome inhibitors in preclinical models. We evaluated the feasibility of combining the proteasome inhibitor, bortezomib, with chemotherapy.
Wan‐Ling Ho +38 more
wiley +1 more source
The Development of Tyrosyl-DNA Phosphodiesterase 1 Inhibitors. Combination of Monoterpene and Adamantine Moieties via Amide or Thioamide Bridges [PDF]
, 2019 Eleven amide and thioamide derivatives with monoterpene and adamantine substituents were synthesised. They were tested for their activity against the tyrosyl-DNA phosphodiesterase 1 DNA (Tdp1) repair enzyme with the most potent compound 47a, having an ...
Reynisson
core +1 more source